Tag: Africa

1. In-hospital mortality within 30 days of admission for COVID-19 was 48% (vs. global mortality 31.5%). 2. Increased age, underlying comorbidities and delay in admission were associated with an increased mortality rate among African patients. Evidence Rating Level: 2 (Good) Study Rundown: The COVID-19 pandemic has exposed long-standing inequities in healthcare. Critically...
1. Vaccine efficacy at 6 months for R21/MM was 74% in group 1 and 77% in group 2. 2. R21/MM showed high malaria-specific antibody titers at 28 days after the third vaccination, which doubled with higher adjuvant doses. Evidence Rating Level: 1 (Excellent) Study Rundown: The development of an effective vaccine against...
1. Analysis of the two distinct waves of the COVID-19 pandemic in Africa showed a more severe second wave with less stringent public health measures in place. 2. The pandemic had a diverse effect on the different regions of Africa, such as an increased prevalence of cases in the Southern...
1. Implementation of seasonal malaria chemoprevention was associated with reductions in malaria cases and deaths during high transmission periods. 2. Seasonal malaria chemoprevention for children in the sub-Sahel regions of Africa demonstrated an overall cost of $3.63 USD per child. Evidence Rating Level: 2 (Good) Study Rundown: The sub-Sahel region of Africa,...
1. In African children with uncomplicated severe anemia, immediate blood transfusion did not notably alter patient mortality at 1- or 6-months post treatment compared to patients treated under current practice. 2. Rates of hospital readmission, serious adverse events, and hemoglobin recovery were similar between the two groups. Evidence Rating Level: 1...
1. In African children with uncomplicated severe anemia, immediate blood transfusion did not notably alter patient mortality at 1- or 6-months post treatment compared to patients treated under current practice. 2. Rates of hospital readmission, serious adverse events, and hemoglobin recovery were similar between the two groups. Evidence Rating Level: 1...
1. Mass, twice-yearly administration of azithromycin to children between 1 and 59 months of age in communities in Niger previously not administered azithromycin significantly reduced childhood mortality rates. 2. Communities given azithromycin for a third year, after receiving it the previous 2 years, had no significant change in childhood mortality...
1. Mass, twice-yearly administration of azithromycin to children between 1 and 59 months of age in communities in Niger previously not administered azithromycin significantly reduced childhood mortality rates. 2. Communities given azithromycin for a third year, after receiving it the previous 2 years, had no significant change in childhood mortality...